Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus

Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus : to a Form of Lichen Planus-like Lupus Erythematosus ?

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04356014

Enrollment

Registered

2020-04-21

Start date

2020-04-01

Completion date

2020-12-30

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lichen Planus, Systemic Lupus Erythematosus

Keywords

Palmoplantar keratoderma with livid telangiectatic erythema, Systemic lupus, Subacute lupus erythematosus

Brief summary

Palmoplantar keratoderma (PPK) associated to livid telangiectatic erythema during systemic lupus erythematosus (SLE) and subacute cutaneous lupus erythematosus (SCLE) is a rare phenomenon seldom reported in literature. The investigators hypothesize that clinic-immunologic assessment and detailed investigation of cutaneous biopsy specimen of PPK and erythema of patients suffering from SLE and SCLE could lead to determine more precisely nosological settings of this injury. Report the different therapeutics with efficacy assessment could be helpful to highlight useful treatment for these patients.

Detailed description

Context: Palmoplantar keratoderma (PPK) associated to livid telangiectatic erythema during systemic lupus erythematosus (SLE) is a rare phenomenon seldom reported in literature. To our knowledge no case has been described in subacute cutaneous lupus erythematosus (SCLE) so far. Pathogeny and etiologic origin are not clear: it could be no-specific cutaneous manifestation of SLE, verrucous chilblain lupus, lichen planus, discoid lupus erythematosus lesions, overlap syndrome or coexistence of both diseases. Objective: 1. Determine clinical immunological and histopathological features of patients with PPK and livid telangiectatic erythema-associated suffering from SLE and SCLE 2. Describe the different therapeutics used and efficacy assessment Methods: Multicentric retrospective descriptive study reporting 14 patients with SLE or SCLE suffering from an acral livid erythematosus keratoderma, with clinical data regarding lupus erythematosus and acral keratoderma, immunological blood samples findings and histopathological results of keratoderma and livid erythema biopsies with direct immunofluorescence if performed. The treatments set down in order to heal are noted followed by efficacy assessment: total failure, partial remission, complete remission.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* \> 18 years old * suffering from SLE or SCLE according to 2019 ACR/EULAR criteria * With palmar and or plantar keratoderma with livid telangiectatic erythema

Exclusion criteria

* \< 18 years old * suffering from lupus lesions without SLE or SCLE criteria * without palmar and or plantar keratoderma with livid telangiectatic erythema

Design outcomes

Primary

Measure	Time frame	Description
Determine clinic immunologic features	1 day	Determine clinic immunologic features of patients with PPK and livid telangiectatic erythema-associated suffering from SLE and SCLE.
Determine clinic histopathologic features	1 day	Epidemiologic clinic immunologic histopathologic data

Secondary

Measure	Time frame	Description
Different therapeutics used	1 day	Describe the different therapeutics used. Report of the drug therapy used to heal acral keratoderma for each patient
Different therapeutics efficacy assessment	1 day	Efficacy assessment of the treatments: total failure, partial remission, complete remission

Countries

France

Outcome results